Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of Mexidol® in Long-term Sequential Treatment of Patients in the Acute and Early Recovery Periods of Hemispheric Ischemic Stroke (EPICA)

NCT02793687 is registered in ClinicalTrials.gov with Pharmasoft as lead sponsor.

NCT NCT02793687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02793687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of Mexidol® in Long-term Sequential Treatment of Patients in the Acute and Early Recovery Periods of Hemispheric Ischemic Stroke (EPICA)
Lead sponsor
Pharmasoft
Phase
Phase 3
Overall status
Completed
Start date
March 6, 2015
Completion date
May 27, 2016
Enrollment
150 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke